Biotest
John Hodkinson has a diverse work experience, with their most recent role being the Commercial Director - Intercompany Unit at Biotest AG. Prior to this, they served as the Regional Director for China, South Korea, and Japan. John also held the position of Head of Business Operations for the Region Intercontinental. In addition, John has experience as the Regional Director for Azerbaijan, Kazakhstan, Ukraine, and Uzbekistan, where they were responsible for Biotest's B2B business and achieving ambitious sales targets. Before joining Biotest, they worked at Biotest UK Ltd as the Medical and Scientific Affairs Manager and as a Medical Advisor. John'searly career includes a role as a Research Scientist at the University of Leeds and a Pre-reg Pharmacist at the Great Ormond Street Hospital for Children NHS Trust.
John Hodkinson's education history includes receiving a Certificate in Global Management from INSEAD in 2018-2019. Prior to this, they pursued an MSc in Immunology and Immunogenetics from The University of Manchester from 2012 to 2014. John also holds a PhD in Structural and Molecular Biology from the University of Leeds, completed between 2005 and 2009. In 2000-2004, they earned an MPharm in Pharmacy from UCL. Additionally, John has obtained a Distance Learning Certificate in Design and Interpretation of Clinical Trials from The Johns Hopkins University, and a Distance Learning degree in Health Technology Assessment from The University of Sheffield, both without specified end years.
This person is not in any teams
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.